Alan Kotok, Publications, 2014

  • LinkedIn. Job Loyalty Revisited: Earned, not Entitled. 7 September 2014. Employers face the challenge of creating an environment where job security and career advancement are more the norm than the exception. Career advancement is something managers at all levels can provide, and often without incurring much expense.
  • LinkedIn. Job Loyalty Revisited: Lessons from Market Basket. 1 September 2014. For American workers, the Market Basket story should raise a few questions about loyalty owed to an employer, and restoring some of the balance that seems weighted way in favor of the people signing pay checks.
  • Seeking Alpha. Sanofi Bolsters Vaccine Business. 18 August 2014. Sanofi Pasteur, the pharmaceutical company's vaccines division, has important new releases coming up in late-stage clinical trials and for regulatory review.
  • Seeking Alpha. Shire Acquisition Bolsters Its Rare, And Maybe Not-So-Rare, Disease Portfolio. 19 May 2014. The acquisition by Shire plc earlier this month of Lumena Pharmaceuticals builds Shire's already strong position in rare diseases, but the acquisition can also help Shire advance drug development programs aimed at larger populations.
  • LinkedIn. My Mission: Journalists Who Love Math. 26 April 2014. For too many reporters of all kinds, covering a story with any amount of quantification seems to make them surrender to the words in a press release. I'm on a mission to change that.
  • Seeking Alpha. New GlaxoSmithKline Diabetes Drug Needs Innovative Marketing Strategy. 21 April 2014. A diabetes drug approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company, one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
  • Seeking Alpha. Myriad Genetics' Acquisition Of Crescendo Bioscience: A Question Of Timing. 10 February 2014. "At first glance, the acquisition makes a lot of sense for Myriad, adding a ready-made capability in a complementary line, but also this week, the scientific landscape changed markedly for rheumatoid arthritis and similar disorders, adding a wrinkle into Myriad's plans for the company."

More articles, by year:
2014 | 2013 | 2009-12 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002
2000-2001 | 1990-1999 | -1989